Highest-materiality recent filing
Ocugen closes $130M of 6.75% convertible senior notes due 2034, net proceeds ~$112.6M
Closed $130.0M aggregate principal of 6.75% Convertible Senior Notes due 2034, including full $15M over-allotment exercise.
Ocugen completes $115M convertible note offering at 6.75%, repays Avenue loan
$115M aggregate principal of 6.75% Convertible Senior Notes due 2034 issued; net proceeds ~$99.5M.
Ocugen posts Q1 loss, details positive Phase 2 GA data, prices $115M notes
Net loss of $(0.06) per share for Q1 2026; cash, cash equivalents, and restricted cash of $32.2M as of March 31, 2026.
Ocugen plans $115M convertible notes offering; preliminary cash $32.2M
Offering of $115M convertible senior notes due 2034, with initial purchaser option for additional $15M.
31% reduction in GA lesion growth (medium dose) vs control at 12 months (p<0.05); 55% of treated patients had ≥30% lesion reduction.
Ocugen raises $15M via partial warrant exercise; cash runway extended to Q1 2027
Investor exercised warrants for 10,000,000 shares of common stock on March 12, 2026, raising $15.0M gross proceeds.
Ocugen Q4 2025 net loss $0.06/share; OCU400 Phase 3 enrollment complete; cash $18.9M
Fourth quarter 2025 net loss $0.06 per share (vs $0.05 Q4 2024); full year net loss $0.23 per share (vs $0.20).
Ocugen files Section 205 petition to validate share increase; hearing set for May 6, 2026
Petition seeks validation of Charter Amendment increasing authorized common shares from 295M to 390M, approved at June 2024 annual meeting.
Ocugen prices $22.5M common stock offering at $1.50/share; led by RTW Investments
Priced 15M shares of common stock at $1.50/share for gross proceeds of $22.5M; net proceeds ~$20.8M.
Ocugen: OCU410 shows 46% GA lesion reduction in Phase 2; Phase 1 EZ loss 60% slower
Phase 2 preliminary 12-month data (N=23) shows 46% GA lesion growth reduction vs control (p=0.015); medium dose 54% (p=0.02), high dose 36% (p=0.05).
Ocugen Q3 net loss $20M; OCU400 Phase 3 nearing completion, Kwangdong deal signed
Net loss of $20.0M ($0.07/sh) vs $13.0M ($0.05) in Q3 2024; cash $32.9M as of Sep 30 (down from $58.8M Dec 31).
Ocugen-Carisma merger terminated after Ocugen failed to secure $25M investment
Carisma terminated Merger Agreement on Sep 16, 2025 because Ocugen obtained less than $25M in commitments for the Concurrent Investment.
Exclusive license to Kwangdong for OCU400 (retinitis pigmentosa gene therapy) in South Korea.
Ocugen announces $20M registered direct offering of 20M shares + warrants to Janus Henderson
Gross proceeds $20M from 20M shares at $1.00 per share (Aug 7 close); warrants to buy 20M shares at $1.50, expiring 2 years.
Ocugen reports Q2 2025 results; cash $27.3M; initiates OCU410ST Phase 2/3 trial
Cash, cash equivalents and restricted cash $27.3M as of June 30, 2025, down from $58.8M at Dec 31, 2024; cash runway into Q1 2026.
Ocugen wins dismissal with prejudice of securities class action lawsuit
U.S. District Court for Eastern District of Pennsylvania granted dismissal with prejudice on July 29, 2025.
Ocugen regains Nasdaq minimum bid price compliance; deficiency matter closed
Received notice on July 28, 2025 that closing bid price met $1.00 minimum for ten consecutive business days July 8–25, 2025.
Ocugen's OrthoCellix to merge with Carisma in reverse merger; combined entity to focus on NeoCart
OrthoCellix valued at $135M; Carisma at $15M; post-merger Ocugen/investors own ~90%, Carisma holders ~10%.
Mean change in LLVA from baseline improved in treated eye vs untreated (p=0.005 at Year 1).
Upfront license fees and near-term development milestones up to $11M.
Ocugen Q1 2025 net loss $0.05/sh; cash $38.1M; OCU400 Phase 3 on track for mid-2026 BLA/MAA
Cash & restricted cash $38.1M as of Mar 31, 2025, down from $58.8M at Dec 31, 2024; runway into Q1 2026.
Ocugen presents clinical trial data at Eyecelerator conference
Presentation furnished as Exhibit 99.1; used at May 2, 2025 Eyecelerator showcase.
Ocugen FY2024 net loss $0.20; advances three gene therapy programs toward BLA filings
Q4 net loss $0.05/share; full-year net loss $0.20/share vs $0.26 in 2023.
Ocugen posts clinical presentation showing 84% reduction in mean total atrophy area in treated group
Presentation reports mean change in total atrophy area from baseline: 0.12±0.36 mm² (treated) vs 0.73±0.26 mm² (untreated), an 84% difference.
Ocugen enters $30M term loan facility with Avenue Capital; issues 1.06M shares to lenders
Term loans of $30M from Avenue Capital at prime + 4.25% (prime floor at closing), maturing Nov 1, 2028.
Ocugen posts corporate presentation showing positive retinal gene therapy data
Mean change in total atrophy area: treated 0.12±0.36 mm2 vs untreated 0.73±0.26 mm2 (84% less progression).
Ocugen receives Nasdaq bid price deficiency notice; has until June 30, 2025 to cure
Nasdaq notified Ocugen on Dec 31, 2024, that its stock closed below $1.00 for 30 consecutive business days.
Ocugen releases presentation with clinical data showing treatment benefit in retinal disease studies
Presentation shows mean change in total atrophy area from baseline reduced by 84% in treated group (0.12 mm²) vs untreated (0.73 mm²).
Ocugen presents positive OCU400 clinical data: 84% less atrophy area in treated vs untreated
OCU400 (AAV encoding NR2E3) shows restoration of phototransduction genes and improved retinal structure in multiple RP/LCA models.
Ocugen closes $30M credit facility with Avenue Capital; proceeds for clinical development
Term loans of $30M fully funded on Nov 6, 2024; maturity Nov 1, 2028; interest rate prime + 4.25% (floor at closing prime).
Ocugen Q3 2024 cash $39M; extends runway into 1Q2026 on $65M in financings
Cash and restricted cash $39.0M as of Sept 30, 2024, vs $39.5M at Dec 31, 2023.
Ocugen reports Q2 net loss $0.04/sh; advances OCU400 Phase 3 trial, raises $32.6M
Net loss per share $0.04 in Q2 2024 versus $0.10 in Q2 2023; total operating expenses $16.6M, down from $24.0M.
Ocugen gets FDA nod to begin expanded access program for OCU400 in retinitis pigmentosa
FDA approved expanded access program for OCU400 for adult RP patients 18+ with minimal retinal preservation.
Ocugen prices $35M public offering of 30.4M shares at $1.15 per share
Gross proceeds of $35M; net proceeds expected ~$32.6M after underwriting discounts.
Ocugen's auditor EY declines re-election for FY2024; company begins search for new auditor
EY notified Ocugen on May 31, 2024 it will not stand for re-election as auditor for fiscal year 2024, ceasing after filing Q2 2024 10-Q.
Effective May 29, 2026, Ramesh Ramachandran, CPA, MBA, CMA, resigned as the Chief Accounting Officer of Ocugen, Inc.
on June 3, 2026, Rita Johnson-Greene, MBA, the Company’s Chief Financial Officer, was appointed as the Company’s principal accounting officer.
Effective May 8, 2026, Huma Qamar, M.D., MPH, CMI, separated from Ocugen, Inc. (the “Company”) as its Chief Medical Officer.
The Board plans to nominate Satish Chandran, Ph.D. and Blaise Coleman for election to the Board at the 2025 Annual Meeting to replace Dr. Fernandes and Dr. Whittington.
Separately, on April 21, 2025, Marna C. Whittington, Ph.D., a member of the Board, the Compensation Committee of the Board, and a member and chair of the Audit Committee of the Board, informed the Company of her decision to not stand for re-election to the Board at the Company’s 2025 Annual Meeting.
Prabha Fernandes, Ph.D., FIDSA, a member of the Board of Directors (the “Board”) of Ocugen, Inc. (the “Company”), a member and chair of the Compensation Committee of the Board, a member of the Audit Committee of the Board and the Science and Technology Committee of the Board, informed the Company that she is resigning from the Board effective at the Company’s 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”).
The Board plans to nominate Satish Chandran, Ph.D. and Blaise Coleman for election to the Board at the 2025 Annual Meeting to replace Dr. Fernandes and Dr. Whittington.
Michael Breininger, the Company’s Corporate Controller, will no longer serve as the principal financial officer and principal accounting officer of the Company.
the Board of Directors of Ocugen, Inc. (the “ Company ”) appointed Ramesh Ramachandran to serve as the Company’s principal financial officer and principal accounting officer
Ramesh Kumar, PhD, a member of the board of directors (the “Board of Directors”) since 2019 notified Ocugen, Inc. (the “Company”) that he will not stand for re-election as a director of the Company upon the expiration of his current term, which expires at the Company’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”).
Max materiality 0.85 · Median 0.62 · Most common event other_material